The primary objective of this study is to evaluate the long-term efficacy, safety, and tolerability of repeated administration of adalimumab in subjects with Crohn’s disease who participated in and successfully completed Study M14-115.
The secondary objective is to assess pharmacokinetics and immunogenicity of adalimumab following subcutaneous administration.